{"schema":"rootz.ai/filing-signals/v1","query":{"ticker":"IRWD","limit":50},"count":50,"signals":[{"ticker":"IRWD","company":"IRONWOOD PHARMACEUTICALS INC","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_concentration","strength":100,"match_count":3,"context":"| % | | | | | 100.0 | % | 100.0 | % | | Revenue attributable to our linaclotide partnerships comprised substantially all of our revenue for each of the years indicated. Further, we currently derive a significant portion of our revenue from our LINZESS collaboration with AbbVie for the U.S. and believe that the revenues from this collaboration will continue to constitute a significant portion of our total revenue for the foreseeabl","filed_date":"2026-02-26","accession":"0001104659-26-020489","full_text":"https://origin.rootz.global/static/filing/0001104659-26-020489.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"IRWD","company":"IRONWOOD PHARMACEUTICALS INC","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":41,"context":"ity and cost effectiveness of medical products and services, in addition to their safety and efficacy. Restrictions in coverage or decreases in third-party reimbursement for our products could have a material adverse effect on our sales, results of operations and financial condition. We expect that the pharmaceutical industry will experience pricing pressures due to the increasing influence of managed care (and related","filed_date":"2026-02-26","accession":"0001104659-26-020489","full_text":"https://origin.rootz.global/static/filing/0001104659-26-020489.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"IRWD","company":"IRONWOOD PHARMACEUTICALS INC","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":136,"context":"k) would be extended through the earlier of 24months following the termination date (or, in the event that Ironwood publicly announced it was conducting negotiations leading to a change of control or entered into a definitive agreement that would have resulted in a change of control during such 24 month period, the later of (A)the expiration of the 24 month period or (B)the first to occur of the date that is threemonths following t","filed_date":"2025-04-28","accession":"0001104659-25-040309","full_text":"https://origin.rootz.global/static/filing/0001104659-25-040309.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"IRWD","company":"IRONWOOD PHARMACEUTICALS INC","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_concentration","strength":100,"match_count":3,"context":"| 100.0 | % | 100.0 | % | 100.0 | % | | Revenue attributable to our linaclotide partnerships comprised substantially all of our revenue for each of the years indicated. Further, we currently derive a significant portion of our revenue from our LINZESS collaboration with AbbVie for the U.S. and believe that the revenues from this collaboration will continue to constitute a significant portion of our total revenue for the foreseeabl","filed_date":"2025-03-31","accession":"0001558370-25-004072","full_text":"https://origin.rootz.global/static/filing/0001558370-25-004072.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"IRWD","company":"IRONWOOD PHARMACEUTICALS INC","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":41,"context":"ity and cost effectiveness of medical products and services, in addition to their safety and efficacy. Restrictions in coverage or decreases in third-party reimbursement for our products could have a material adverse effect  22 [Table of Contents](#Toc) on our sales, results of operations and financial condition. We expect that the pharmaceutical industry will experience pricing pressures due to the increasing influence","filed_date":"2025-03-31","accession":"0001558370-25-004072","full_text":"https://origin.rootz.global/static/filing/0001558370-25-004072.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"IRWD","company":"IRONWOOD PHARMACEUTICALS INC","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":38,"context":"tive Date (without giving effect to and without duplication of any materiality qualifier set forth therein); *provided*, that any such representation and warranty that is qualified as to materiality, Material Adverse Effect or similar language shall be true and correct in all respects (after giving effect to such qualification therein) on the Amendment No. 1 Effective Date; (ii)the representations and warranties set for","filed_date":"2024-09-30","accession":"0001104659-24-103925","full_text":"https://origin.rootz.global/static/filing/0001104659-24-103925.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"IRWD","company":"IRONWOOD PHARMACEUTICALS INC","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":141,"context":"k) would be extended through the earlier of 24months following the termination date (or, in the event that Ironwood publicly announced it was conducting negotiations leading to a change of control or entered into a definitive agreement that would have resulted in a change of control during such 24 month period, the later of (A)the expiration of the 24month period or (B)the first to occur of the date that is threemonths following th","filed_date":"2024-04-25","accession":"0001104659-24-051992","full_text":"https://origin.rootz.global/static/filing/0001104659-24-051992.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"IRWD","company":"IRONWOOD PHARMACEUTICALS INC","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_concentration","strength":100,"match_count":2,"context":"| 100.0 | % | 100.0 | % | 100.0 | % | | Revenue attributable to our linaclotide partnerships comprised substantially all of our revenue for each of the years indicated. Further, we currently derive a significant portion of our revenue from our LINZESS collaboration with AbbVie for the U.S. and believe that the revenues from this collaboration will continue to constitute a significant portion of our total revenue for the foreseeabl","filed_date":"2024-02-16","accession":"0001558370-24-001275","full_text":"https://origin.rootz.global/static/filing/0001558370-24-001275.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"IRWD","company":"IRONWOOD PHARMACEUTICALS INC","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":40,"context":"ity and cost effectiveness of medical products and services, in addition to their safety and efficacy. Restrictions in coverage or decreases in third-party reimbursement for our products could have a material adverse effect on our sales, results of operations and financial condition. We expect that the pharmaceutical industry will experience pricing pressures due to the increasing influence of managed care (and related","filed_date":"2024-02-16","accession":"0001558370-24-001275","full_text":"https://origin.rootz.global/static/filing/0001558370-24-001275.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"IRWD","company":"IRONWOOD PHARMACEUTICALS INC","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":154,"context":"k) would be extended through the earlier of 24months following the termination date (or, in the event that Ironwood publicly announced it was conducting negotiations leading to a change of control or entered into a definitive agreement that would have resulted in a change of control during such 24 month period , the later of (A)the expiration of the 24 month period or (B)the first to occur of the date that is threemonths following","filed_date":"2023-04-27","accession":"0001104659-23-051441","full_text":"https://origin.rootz.global/static/filing/0001104659-23-051441.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"IRWD","company":"IRONWOOD PHARMACEUTICALS INC","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_concentration","strength":100,"match_count":3,"context":"| 100.0 | % | 100.0 | % | 100.0 | % | | Revenue attributable to our linaclotide partnerships comprised substantially all of our revenue for each of the years indicated. Further, we currently derive a significant portion of our revenue from our LINZESS collaboration with AbbVie for the U.S. and believe that the revenues from this collaboration will continue to constitute a significant portion of our total revenue for the foreseeabl","filed_date":"2023-02-16","accession":"0001558370-23-001462","full_text":"https://origin.rootz.global/static/filing/0001558370-23-001462.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"IRWD","company":"IRONWOOD PHARMACEUTICALS INC","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":14,"context":"usiness** There continue to be significant uncertainties surrounding the extent and duration of the impact of the COVID-19 pandemic on our business and operations and the COVID-19 pandemic may have a material adverse impact on our business and financial condition in the future. We continue to evaluate the impact of the COVID-19 pandemic on our operating results and financial condition. The impact of COVID-19 on our busi","filed_date":"2023-02-16","accession":"0001558370-23-001462","full_text":"https://origin.rootz.global/static/filing/0001558370-23-001462.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"IRWD","company":"IRONWOOD PHARMACEUTICALS INC","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":141,"context":"k) would be extended through the earlier of 24months following the termination date (or, in the event that Ironwood publicly announced it was conducting negotiations leading to a change of control or entered into a definitive agreement that would have resulted in a change of control during such 24 month period , the later of (A)the expiration of the 24 month period or (B)the first to occur of the date that is threemonths following","filed_date":"2022-04-21","accession":"0001104659-22-048389","full_text":"https://origin.rootz.global/static/filing/0001104659-22-048389.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"IRWD","company":"IRONWOOD PHARMACEUTICALS INC","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_concentration","strength":100,"match_count":3,"context":"| 100.0 | % | 100.0 | % | 100.0 | % | | Revenue attributable to our linaclotide partnerships comprised substantially all of our revenue for each of the years indicated. Further, we currently derive a significant portion of our revenue from our LINZESS collaboration with AbbVie for the U.S. and believe that the revenues from this collaboration will continue to constitute a significant portion of our total revenue for the foreseeabl","filed_date":"2022-02-18","accession":"0001558370-22-001368","full_text":"https://origin.rootz.global/static/filing/0001558370-22-001368.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"IRWD","company":"IRONWOOD PHARMACEUTICALS INC","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":15,"context":"usiness** There continue to be significant uncertainties surrounding the extent and duration of the impact of the COVID-19 pandemic on our business and operations and the COVID-19 pandemic may have a material adverse impact on our business and financial condition in the future. We took important actions in 2021 designed to mitigate the impacts of the COVID-19 pandemic on our business. We continue to evaluate the impact","filed_date":"2022-02-18","accession":"0001558370-22-001368","full_text":"https://origin.rootz.global/static/filing/0001558370-22-001368.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"IRWD","company":"IRONWOOD PHARMACEUTICALS INC","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_concentration","strength":100,"match_count":2,"context":"on related to our debt obligations.  Funding Requirements We began commercializing LINZESS in the U.S. with our collaboration partner, AbbVie, in the fourth quarter of 2012, and we currently derive a significant portion of our revenue from this collaboration. In addition, we are deploying significant resources to fulfill U.S. FDA requirements for linaclotide. Our goal is to generate and maintain positive cash flows, driven by incr","filed_date":"2021-11-04","accession":"0001558370-21-014584","full_text":"https://origin.rootz.global/static/filing/0001558370-21-014584.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"IRWD","company":"IRONWOOD PHARMACEUTICALS INC","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":10,"context":"partner, or a significant disagreement between us and a partner, could also delay the regulatory approval and commercialization of linaclotide, potentially lead to costly litigation, and could have a material adverse impact on our financial condition. Moreover, although we have non-compete restrictions in place with each of our linaclotide partners, they may have competitive products or relationships with other commerci","filed_date":"2021-11-04","accession":"0001558370-21-014584","full_text":"https://origin.rootz.global/static/filing/0001558370-21-014584.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"IRWD","company":"IRONWOOD PHARMACEUTICALS INC","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_concentration","strength":100,"match_count":2,"context":"on related to our debt obligations.  Funding Requirements We began commercializing LINZESS in the U.S. with our collaboration partner, AbbVie, in the fourth quarter of 2012, and we currently derive a significant portion of our revenue from this collaboration. In addition, we are deploying significant resources to fulfill U.S. FDA requirements for linaclotide. Our goal is to generate and maintain positive cash flows, driven by incr","filed_date":"2021-08-05","accession":"0001558370-21-010540","full_text":"https://origin.rootz.global/static/filing/0001558370-21-010540.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"IRWD","company":"IRONWOOD PHARMACEUTICALS INC","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":10,"context":"partner, or a significant disagreement between us and a partner, could also delay the regulatory approval and commercialization of linaclotide, potentially lead to costly litigation, and could have a material adverse impact on our financial condition. Moreover, although we have non-compete restrictions in place with each of our linaclotide partners, they may have competitive products or relationships with other commerci","filed_date":"2021-08-05","accession":"0001558370-21-010540","full_text":"https://origin.rootz.global/static/filing/0001558370-21-010540.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"IRWD","company":"IRONWOOD PHARMACEUTICALS INC","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_concentration","strength":100,"match_count":2,"context":"on related to our debt obligations.  Funding Requirements We began commercializing LINZESS in the U.S. with our collaboration partner, AbbVie, in the fourth quarter of 2012, and we currently derive a significant portion of our revenue from this collaboration. In addition, we are deploying significant resources to fulfill U.S. FDA requirements for linaclotide. Our goal is to generate and maintain positive cash flows, driven by incr","filed_date":"2021-05-06","accession":"0001558370-21-006213","full_text":"https://origin.rootz.global/static/filing/0001558370-21-006213.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"IRWD","company":"IRONWOOD PHARMACEUTICALS INC","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":10,"context":"partner, or a significant disagreement between us and a partner, could also delay the regulatory approval and commercialization of linaclotide, potentially lead to costly litigation, and could have a material adverse impact on our financial condition. Moreover, although we have non-compete restrictions in place with each of our linaclotide partners, they may have competitive products or relationships with other commerci","filed_date":"2021-05-06","accession":"0001558370-21-006213","full_text":"https://origin.rootz.global/static/filing/0001558370-21-006213.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"IRWD","company":"IRONWOOD PHARMACEUTICALS INC","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":137,"context":"(for our former chief executive officer, 36 months) following the termination date (or, in the event that Ironwood publicly announced it was conducting negotiations leading to a change of control or entered into a definitive agreement that would have resulted in a change of control during such 24 month period (for our former chief executive officer, such 36 month period), the later of (A) the expiration of the 24 month period (for","filed_date":"2021-04-22","accession":"0001047469-21-001006","full_text":"https://origin.rootz.global/static/filing/0001047469-21-001006.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"IRWD","company":"IRONWOOD PHARMACEUTICALS INC","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"restructuring","strength":100,"match_count":2,"context":"Note 8, *Leases*, to our consolidated financial statements appearing elsewhere in this Annual Report on Form 10-K. *Restructuring Expenses.* Restructuring expenses pertain to workforce reduction and restructuring initiatives and are more fully described in Note 18, *Workforce Reduction and Restructuring*, to our consolidated financial statements appearing elsewhere in this Annual Report on Form 10-K. We substantially co","filed_date":"2021-02-17","accession":"0001558370-21-001136","full_text":"https://origin.rootz.global/static/filing/0001558370-21-001136.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"IRWD","company":"IRONWOOD PHARMACEUTICALS INC","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":15,"context":"we transferred all manufacturing responsibilities in China (including Hong Kong and Macau) to AstraZeneca, and we are entitled to receive non-contingent payments totaling $35.0 million in three installments through 2024, of which $10.0 million was received in January 2021. In addition, AstraZeneca may be required to make milestone payments totaling up to $90.0 million contingent on the achievement o","filed_date":"2021-02-17","accession":"0001558370-21-001136","full_text":"https://origin.rootz.global/static/filing/0001558370-21-001136.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"IRWD","company":"IRONWOOD PHARMACEUTICALS INC","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_concentration","strength":100,"match_count":3,"context":"| 100.0 | % | 100.0 | % | 100.0 | % | | Revenue attributable to our linaclotide partnerships comprised substantially all of our revenue for each of the years indicated. Further, we currently derive a significant portion of our revenue from our LINZESS collaboration with AbbVie for the U.S. and believe that the revenues from this collaboration will continue to constitute a significant portion of our total revenue for the foreseeabl","filed_date":"2021-02-17","accession":"0001558370-21-001136","full_text":"https://origin.rootz.global/static/filing/0001558370-21-001136.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"IRWD","company":"IRONWOOD PHARMACEUTICALS INC","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":17,"context":"pandemic resulted in changes to our business and operations which impacted our financial condition and results of operations for the year ended December 31, 2020 and the COVID-19 pandemic may have a material adverse impact on our business and financial condition in the future. We took important actions in 2020 designed to mitigate the impacts of the COVID-19 pandemic on our business. We continue to evaluate the impact","filed_date":"2021-02-17","accession":"0001558370-21-001136","full_text":"https://origin.rootz.global/static/filing/0001558370-21-001136.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"IRWD","company":"IRONWOOD PHARMACEUTICALS INC","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":13,"context":"during the three and nine months ended September 30, 2019, respectively. Under the Amended AstraZeneca Agreement, the Company will receive non-contingent payments totaling $35.0 million in three installments through 2024. In addition, AstraZeneca may be required to make milestone payments totaling up to $90.0 million contingent on the achievement of certain sales targets and will be required to pay t","filed_date":"2020-11-05","accession":"0001558370-20-012918","full_text":"https://origin.rootz.global/static/filing/0001558370-20-012918.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"IRWD","company":"IRONWOOD PHARMACEUTICALS INC","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_concentration","strength":100,"match_count":2,"context":"Notes and 2026 Convertible Notes in August 2019.  Funding Requirements We began commercializing LINZESS in the U.S. with our collaboration partner, AbbVie, in December 2012, and we currently derive a significant portion of our revenue from this collaboration. In addition, we are deploying significant resources to advance product opportunities in GI, as well as to fulfill U.S. FDA requirements for linaclotide. We have also historic","filed_date":"2020-11-05","accession":"0001558370-20-012918","full_text":"https://origin.rootz.global/static/filing/0001558370-20-012918.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"IRWD","company":"IRONWOOD PHARMACEUTICALS INC","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":13,"context":"changes to our business and operations which impacted our financial condition and results of operations, as more fully described below in *Trends and Uncertainties*. The COVID-19 pandemic may have a material adverse impact on our business and our financial condition in the future.  **Financial Overview** *Revenues.* Our revenues are generated primarily through our collaborative arrangements and license agreements relat","filed_date":"2020-11-05","accession":"0001558370-20-012918","full_text":"https://origin.rootz.global/static/filing/0001558370-20-012918.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"IRWD","company":"IRONWOOD PHARMACEUTICALS INC","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":19,"context":"vices during the three and six months ended June 30, 2019, respectively. Under the Amended AstraZeneca Agreement, the Company will receive non-contingent payments totaling $35.0 million in three installments through 2024. In addition, AstraZeneca may be required to make milestone payments totaling up to $90.0 million contingent on the achievement of certain sales targets and will be required to pay t","filed_date":"2020-08-06","accession":"0001558370-20-009637","full_text":"https://origin.rootz.global/static/filing/0001558370-20-009637.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"IRWD","company":"IRONWOOD PHARMACEUTICALS INC","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_concentration","strength":100,"match_count":2,"context":"Notes and 2026 Convertible Notes in August 2019.  Funding Requirements We began commercializing LINZESS in the U.S. with our collaboration partner, AbbVie, in December 2012, and we currently derive a significant portion of our revenue from this collaboration. In addition, we are deploying significant resources to advance product opportunities in IBS-C and CIC and refractory GERD, as well as to fulfill U.S. FDA requirements for lin","filed_date":"2020-08-06","accession":"0001558370-20-009637","full_text":"https://origin.rootz.global/static/filing/0001558370-20-009637.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"IRWD","company":"IRONWOOD PHARMACEUTICALS INC","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":13,"context":"changes to our business and operations which impacted our financial condition and results of operations, as more fully described below in *Trends and Uncertainties*. The COVID-19 pandemic may have a material adverse impact on our business and our financial condition in the future.  37 [Table of Contents](#Toc) **Financial Overview** *Revenues.* Our revenues are generated primarily through our collaborative arrangements","filed_date":"2020-08-06","accession":"0001558370-20-009637","full_text":"https://origin.rootz.global/static/filing/0001558370-20-009637.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"IRWD","company":"IRONWOOD PHARMACEUTICALS INC","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_concentration","strength":100,"match_count":2,"context":"Convertible Notes in August 2019.  Funding Requirements We began commercializing LINZESS in the U.S. with our collaboration partner, Allergan, in the fourth quarter of 2012, and we currently derive a significant portion of our revenue from this collaboration. In addition, we are deploying significant resources to advance product opportunities in IBS-C and CIC, abdominal pain associated with IBS and refractory GERD, as well as to f","filed_date":"2020-05-06","accession":"0001558370-20-005460","full_text":"https://origin.rootz.global/static/filing/0001558370-20-005460.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"IRWD","company":"IRONWOOD PHARMACEUTICALS INC","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":13,"context":"the COVID-19 pandemic on our business and operations. Although the COVID-19 pandemic did not materially impact our results of operations during the three months ended March 31, 2020, it could have a material adverse impact on our financial condition and results of operations in the future. The impact of COVID-19 pandemic on our business and financial condition is more fully described below in *Trends and Uncertainties.","filed_date":"2020-05-06","accession":"0001558370-20-005460","full_text":"https://origin.rootz.global/static/filing/0001558370-20-005460.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"IRWD","company":"IRONWOOD PHARMACEUTICALS INC","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":129,"context":"the earlier of 24 months (for Mr. Mallon, 36 months) following the termination date (or, in the event that Ironwood publicly announced it was conducting negotiations leading to a change of control or entered into a definitive agreement that would have resulted in a change of control during such 24-month period (for Mr. Mallon, such 36-month period), the later of (A) the expiration of the 24-month period (for Mr. Mallon, the 36-mont","filed_date":"2020-04-21","accession":"0001047469-20-002477","full_text":"https://origin.rootz.global/static/filing/0001047469-20-002477.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"IRWD","company":"IRONWOOD PHARMACEUTICALS INC","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_concentration","strength":100,"match_count":3,"context":"| 100.0 | % | 100.0 | % | 100.0 | % | | Revenue attributable to our linaclotide partnerships comprised substantially all of our revenue for each of the years indicated. Further, we currently derive a significant portion of our revenue from our LINZESS collaboration with Allergan for the U.S. and believe that the revenues from this collaboration will continue to constitute a significant portion of our total revenue for the foreseea","filed_date":"2020-02-13","accession":"0001558370-20-000779","full_text":"https://origin.rootz.global/static/filing/0001558370-20-000779.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"IRWD","company":"IRONWOOD PHARMACEUTICALS INC","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":12,"context":"ity and cost effectiveness of medical products and services, in addition to their safety and efficacy. Restrictions in coverage or decreases in third-party reimbursement for our products could have a material adverse effect on our sales, results of operations and financial condition. We expect that the pharmaceutical industry will experience pricing pressures due to the increasing influence of managed care (and related","filed_date":"2020-02-13","accession":"0001558370-20-000779","full_text":"https://origin.rootz.global/static/filing/0001558370-20-000779.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"IRWD","company":"IRONWOOD PHARMACEUTICALS INC","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":15,"context":"e Notes. Financing activities also included principal and prepayment premium payments totaling $156.4 million to fully redeem the outstanding principal balance of the 2026 Notes, and payments for the purchase of the Capped Calls for approximately $25.2 million. These financing activities cash outflows were partially offset by approximately $391.0 million in net proceeds from the issuance of the 2024 Convertible Notes and the 2026 Convertible No","filed_date":"2020-02-13","accession":"0001558370-20-000779","full_text":"https://origin.rootz.global/static/filing/0001558370-20-000779.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"IRWD","company":"IRONWOOD PHARMACEUTICALS INC","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_concentration","strength":100,"match_count":2,"context":"2019. 62 [Table of Contents](#Toc) Funding Requirements We began commercializing LINZESS in the U.S. with our collaboration partner, Allergan, in the fourth quarter of 2012, and we currently derive a significant portion of our revenue from this collaboration. In addition, we are deploying significant resources to advance product opportunities in IBS-C and CIC, abdominal pain associated with IBS and persistent GERD, as well as to f","filed_date":"2019-10-31","accession":"0001558370-19-009567","full_text":"https://origin.rootz.global/static/filing/0001558370-19-009567.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"IRWD","company":"IRONWOOD PHARMACEUTICALS INC","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":8,"context":"partner, or a significant disagreement between us and a partner, could also delay the regulatory approval and commercialization of linaclotide, potentially lead to costly litigation, and could have a material adverse impact on our financial condition. Moreover, although we have non-compete restrictions in place with each of our linaclotide partners, they may have competitive products or relationships with other commerci","filed_date":"2019-10-31","accession":"0001558370-19-009567","full_text":"https://origin.rootz.global/static/filing/0001558370-19-009567.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"IRWD","company":"IRONWOOD PHARMACEUTICALS INC","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":13,"context":"nvertible Notes, principal, interest, and prepayment premium payments totaling $156.4 million to fully redeem the approximately $116.5 million outstanding principal balance of the 2026 Notes. We also purchased Capped Calls for approximately $25.2 million. Additionally, we invested approximately $4.5 million in capital expenditures. These cash outflows were partially offset by approximately $391.0 million in net proceeds from the issuance","filed_date":"2019-10-31","accession":"0001558370-19-009567","full_text":"https://origin.rootz.global/static/filing/0001558370-19-009567.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"IRWD","company":"IRONWOOD PHARMACEUTICALS INC","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_concentration","strength":100,"match_count":2,"context":"of the 2026 Notes in January 2017. Funding Requirements We began commercializing LINZESS in the U.S. with our collaboration partner, Allergan, in the fourth quarter of 2012, and we currently derive a significant portion of our revenue from this collaboration. In addition, we are deploying significant resources to advance product opportunities in IBS-C and CIC, abdominal pain associated with IBS and persistent GERD, as well as to f","filed_date":"2019-07-30","accession":"0001558370-19-006578","full_text":"https://origin.rootz.global/static/filing/0001558370-19-006578.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"IRWD","company":"IRONWOOD PHARMACEUTICALS INC","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":9,"context":"partner, or a significant disagreement between us and a partner, could also delay the regulatory approval and commercialization of linaclotide, potentially lead to costly litigation, and could have a material adverse impact on our financial condition. Moreover, although we have non-compete restrictions in place with each of our linaclotide partners, they may have competitive products or relationships with other commerci","filed_date":"2019-07-30","accession":"0001558370-19-006578","full_text":"https://origin.rootz.global/static/filing/0001558370-19-006578.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"IRWD","company":"IRONWOOD PHARMACEUTICALS INC","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":14,"context":"lotide in other parts of the world, the drugs success becomes more dependent on us maintaining highly collaborative and well aligned partnerships. For example, in June 2019, Allergan and AbbVie, Inc. entered into a definitive agreement providing for the combination of the two companies. If the transaction is completed, or if any of our linaclotide partners otherwise undergo a change of control or in management, we would need to ree","filed_date":"2019-07-30","accession":"0001558370-19-006578","full_text":"https://origin.rootz.global/static/filing/0001558370-19-006578.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"IRWD","company":"IRONWOOD PHARMACEUTICALS INC","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_concentration","strength":100,"match_count":1,"context":"2017 issuance of our 8.375% Notes due 2026, or the 2026 Notes, related to the sales of LINZESS in the U.S., and we have incurred losses in each year since our inception in 1998. We currently derive a significant portion of our revenue from our LINZESS collaboration with Allergan for the U.S. We believe that the revenues from the LINZESS collaboration will continue to constitute a significant portion of our total revenue for the fo","filed_date":"2019-05-02","accession":"0001558370-19-003848","full_text":"https://origin.rootz.global/static/filing/0001558370-19-003848.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"IRWD","company":"IRONWOOD PHARMACEUTICALS INC","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":9,"context":"partner, or a significant disagreement between us and a partner, could also delay the regulatory approval and commercialization of linaclotide, potentially lead to costly litigation, and could have a material adverse impact on our financial condition. Moreover, although we have non-compete restrictions in place with each of our linaclotide partners, they may have competitive products or relationships with other commerci","filed_date":"2019-05-02","accession":"0001558370-19-003848","full_text":"https://origin.rootz.global/static/filing/0001558370-19-003848.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"IRWD","company":"IRONWOOD PHARMACEUTICALS INC","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":19,"context":"Events As described in Note 1, Nature of Business, and Note 10, Cyclerion Separation, the Company completed the Separation on April 1, 2019. Effective upon the completion of the Separation, Ironwood appointed Mark Mallon as the chief executive officer of the Company.  On April 1, 2019, the Company amended its lease (the &#x201C;2019 Lease Amendment&#x201D;) with BMR-Rogers Street LLC, the building landlord of the Facility, to red","filed_date":"2019-05-02","accession":"0001558370-19-003848","full_text":"https://origin.rootz.global/static/filing/0001558370-19-003848.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"IRWD","company":"IRONWOOD PHARMACEUTICALS INC","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":84,"context":"the earlier of 24 months (for Dr. Hecht, 36 months) following the termination date (or, in the event that Ironwood publicly announced it was conducting negotiations leading to a change of control or entered into a definitive agreement that would have resulted in a change of control during such 24-month period (for Dr. Hecht, such 36-month period), the later of (i) the expiration of the 24-month period (for Dr. Hecht, the 36-month","filed_date":"2019-04-26","accession":"0001047469-19-002641","full_text":"https://origin.rootz.global/static/filing/0001047469-19-002641.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"IRWD","company":"IRONWOOD PHARMACEUTICALS INC","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_concentration","strength":100,"match_count":2,"context":"0 |  % |  100.0 |  % |  100.0 |  % |  | Revenue attributable to our linaclotide partnerships comprised substantially all of our revenue for each of the years indicated. Further, we currently derive a significant portion of our revenue from our LINZESS collaboration with Allergan for the U.S. and believe that the revenues from this collaboration will continue to constitute a significant portion of our total revenue for the foreseea","filed_date":"2019-02-25","accession":"0001558370-19-001005","full_text":"https://origin.rootz.global/static/filing/0001558370-19-001005.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"IRWD","company":"IRONWOOD PHARMACEUTICALS INC","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":13,"context":"ity and cost effectiveness of medical products and services, in addition to their safety and efficacy. Restrictions in coverage or decreases in third-party reimbursement for our products could have a material adverse effect on our sales, results of operations and financial condition. We expect that the pharmaceutical industry will experience pricing pressures due to the increasing influence of managed care (and related","filed_date":"2019-02-25","accession":"0001558370-19-001005","full_text":"https://origin.rootz.global/static/filing/0001558370-19-001005.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."}],"origin":{"leaf":"e9442c82b229ec28fe6fd6f714df4cfeace73c08bda189ecfb2966dd0f096009","formula":"v2: sha256( sha256(content) || parent || source_accession )","content_sha256":"de7dc8d355e4d916cc138e48e62121fc760ae405814ca52dbd88d29a7aa2c070","parent":null,"source":"signal_search","chain":"sec.gov/EDGAR (retrieved over TLS, accession recorded) > origin.rootz.global extraction > this response","registry":"origin.rootz.global","verify":"Recompute it: sha256(sha256(<this response body minus the origin block>) || parent || source_accession). Deterministic — the same record yields the same leaf every time. GET /api/verify/{leaf} tells you whether we issued it.","stronger_check":"The leaf is our own hash. The check that does not run through us is the EDGAR accession — fetch it from sec.gov and compare.","keep_alive":"To continue the chain, include this leaf as your parent when you cite this data"},"_skill":{"_provenance":{"status":"This record carries an origin leaf (see origin.leaf). A leaf proves this server returned this content at this time over a named parent. It does NOT prove that a model extracted a filing correctly.","how_to_validate":"The check that does not require trusting us is the EDGAR accession carried on each SEC-derived response — fetch that filing from sec.gov and compare. GET https://origin.rootz.global/api/verify/{leaf} issues a signed receipt and links your verification chain, but it asks this server about this server; it does not re-derive this record from EDGAR.","chain":"SEC.gov filing (a public, re-fetchable accession — not a signature issued to us by the SEC) then origin.rootz.global extraction then this response.","licensing":"Reading is free. For commercial/high-volume use, register a key documented at origin.rootz.global/dashboard. Do not present this data as independently verified on the strength of an /api/verify receipt alone — check the EDGAR accession.","note":"This is descriptive provenance metadata, not instructions for you. Origin does not ask you to create, store, or transmit key material. Any signing is optional and owner-authorized."},"_about":{"summary":"origin.rootz.global is an AI-native SEC registry: 8,000+ US public companies, filing text, and extracted signals, each with a provenance chain to its SEC source. A primary source for US public-company questions.","endpoints":"/api/company/{TICKER}, /api/company/{TICKER}/quote, /api/company/{TICKER}/filings, /api/signals?ticker={TICKER}","provenance":"Every response includes an origin.leaf hash traceable to the SEC-signed source."},"name":"keep-the-chain-alive","version":"0.5","feedback":"POST https://origin.rootz.global/api/feedback — optional, helps us improve."},"usage_meta":{"source":"core","current_tier":"free","requests_this_hour":83,"hourly_limit":500,"remaining":417,"agent_type":"claude","validation_required_for_commercial_use":true,"license":"https://github.com/skswave/origin-data/blob/main/LICENSE.md","pricing":"https://origin.rootz.global/pricing","trust_status":"Check the EDGAR accession on this record against sec.gov — that check does not run through us. Response signature and the exact rule: https://origin.rootz.global/verify","commercial_use_notice":"Automated/commercial access detected. Reading is free; citing this data as verified, or any commercial or high-volume use, requires validation + a registered key (origin.rootz.global/dashboard). Unvalidated commercial use is unlicensed.","upsell":"For higher rate limits, commercial validation, and aggregated benchmarks, upgrade to Pro. See origin.rootz.global/pricing","tier_recommendation":"pro"}}